Medivir Valuation

Is 0GP7 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0GP7 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0GP7's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0GP7's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0GP7?

Key metric: As 0GP7 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0GP7. This is calculated by dividing 0GP7's market cap by their current revenue.
What is 0GP7's PS Ratio?
PS Ratio	45.1x
Sales	SEK 7.73m
Market Cap	SEK 348.84m

0GP7 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	26.6x
Enterprise Value/EBITDA	-2.1x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 0GP7's PS Ratio compare to its peers?

The above table shows the PS ratio for 0GP7 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	11.2x
ONC Oncimmune Holdings	14.1x	105.1%	UK£17.2m
OPTI OptiBiotix Health	21.5x	n/a	UK£12.2m
TRX Tissue Regenix Group	1.6x	15.1%	UK£40.6m
APTA Aptamer Group	7.6x	n/a	UK£6.5m
0GP7 Medivir	45.1x	58.8%	SEK 348.8m

Price-To-Sales vs Peers: 0GP7 is expensive based on its Price-To-Sales Ratio (45.1x) compared to the peer average (15.6x).

Price to Sales Ratio vs Industry

How does 0GP7's PS Ratio compare vs other companies in the GB Biotechs Industry?

6 Companies	Price / Sales	Estimated Growth	Market Cap
GNS Genus	1.7x	3.5%	US$1.41b
OXB Oxford Biomedica	4.5x	21.0%	US$554.49m
TRX Tissue Regenix Group	1.6x	15.1%	US$50.88m
PBX ProBiotix Health	4.8x	n/a	US$12.88m

6 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 0GP7 is expensive based on its Price-To-Sales Ratio (45.1x) compared to the European Biotechs industry average (9.6x).

Price to Sales Ratio vs Fair Ratio

What is 0GP7's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0GP7 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	45.1x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 0GP7's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Formycon

€827.2m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€47.10

1.3%

-23.5%

hVIVO

UK£149.7m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.22

-13.4%

17.3%

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€62.90

1.0%

13.3%